MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis (MAINRITSAN)

NCT00748644 Phase 3 COMPLETED

Study of the efficacy of rituximab for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized comparative study of rituximab versus azathioprine

Details

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	COMPLETED
Enrolment	117
Start date	2008-10
Completion	2013-06

Conditions

• Wegener Granulomatosis
• Microscopic Polyangiitis

Interventions

• Rituximab
• Azathioprine

Primary outcomes

• Number of major relapse (BVAS>10) in each group at the end of the maintenance treatment (18 months treatment + 10 months follow-up) — 28 months

Countries

France